Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, Dover G, Mays A, Zwiebel J, Murgo A, Weng LJ, Herman JG. Gore SD, et al. Among authors: karp je. Cancer Res. 2006 Jun 15;66(12):6361-9. doi: 10.1158/0008-5472.CAN-06-0080. Cancer Res. 2006. PMID: 16778214
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith BD, Ironside V, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei AA, Gore SD, Levis MJ, Wright JJ, Garrett-Mayer E, Kaufmann SH. Karp JE, et al. Blood. 2009 May 14;113(20):4841-52. doi: 10.1182/blood-2008-08-172726. Epub 2008 Dec 24. Blood. 2009. PMID: 19109557 Free PMC article. Clinical Trial.
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.
Smith BD, Jones RJ, Cho E, Kowalski J, Karp JE, Gore SD, Vala M, Meade B, Baker SD, Zhao M, Piantadosi S, Zhang Z, Blumenthal G, Warlick ED, Brodsky RA, Murgo A, Rudek MA, Matsui WH. Smith BD, et al. Among authors: karp je. Leuk Res. 2011 Jan;35(1):87-94. doi: 10.1016/j.leukres.2010.06.001. Epub 2010 Jul 3. Leuk Res. 2011. PMID: 20598742 Free PMC article. Clinical Trial.
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.
Karp JE, Smith BD, Resar LS, Greer JM, Blackford A, Zhao M, Moton-Nelson D, Alino K, Levis MJ, Gore SD, Joseph B, Carraway H, McDevitt MA, Bagain L, Mackey K, Briel J, Doyle LA, Wright JJ, Rudek MA. Karp JE, et al. Blood. 2011 Mar 24;117(12):3302-10. doi: 10.1182/blood-2010-09-310862. Epub 2011 Jan 14. Blood. 2011. PMID: 21239698 Free PMC article. Clinical Trial.
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.
Zeidan AM, Ricklis RM, Carraway HE, Yun HD, Greer JM, Smith BD, Levis MJ, McDevitt MA, Pratz KW, Showel MM, Gladstone DE, Gore SD, Karp JE. Zeidan AM, et al. Among authors: karp je. Br J Haematol. 2012 Jul;158(2):198-207. doi: 10.1111/j.1365-2141.2012.09142.x. Epub 2012 May 18. Br J Haematol. 2012. PMID: 22594769 Free PMC article. Clinical Trial.
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Smith BD, Greer JM, Drye DM, Mackey K, Dorcy KS, Gore SD, Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showel MM, Othus M, Doyle LA, Wright JJ, Pagel JM. Karp JE, et al. Haematologica. 2012 Nov;97(11):1736-42. doi: 10.3324/haematol.2012.062539. Epub 2012 Jun 24. Haematologica. 2012. PMID: 22733022 Free PMC article. Clinical Trial.
290 results